

**88th ANNUAL CONGRESS
OF THE SWISS SOCIETY OF PATHOLOGY**

**88. JAHRESTAGUNG DER SCHWEIZERISCHEN
GESELLSCHAFT FÜR PATHOLOGIE**

**88^e CONGRÈS ANNUEL
DE LA SOCIÉTÉ SUISSE DE PATHOLOGIE**

November 9-11, 2023

Pathology – Science in Motion

**IIII
BEAULIEU**

Centre de Congrès de Beaulieu, Lausanne

program



SGPath | SSPath

SOCIÉTÉ SUISSE DE PATHOLOGIE
SCHWEIZERISCHE GESELLSCHAFT FÜR PATHOLOGIE
SWISS SOCIETY OF PATHOLOGY

Online registration / Anmeldungen / Inscriptions

www.meeting-com.ch

Welcome

Dear Colleagues and Friends,

On behalf of the Swiss Society of Pathology, it is our great pleasure to invite you to attend the 88th Annual Meeting of the Society to be held in Lausanne from Thursday, November 9th, through Saturday, November 11th, 2023.

The scientific program has been developed around the theme “Pathology - Science in Motion” to highlight the dynamic changes taking place in our specialty that impact on diagnostic practice, as well as the rapid increase in data generation and knowledge enabled by novel technologies that advance analytical resolution and dimensionality. The session on Quantitative and Functional Pathology, organized in conjunction with the Swiss Digital Pathology Consortium, will focus on new emerging standards and modalities that link morphology and tissue analysis to molecular medicine.

The postgraduate course “Neuropathology for Surgical Pathologists and Clinicians” will precede the main meeting on Thursday morning as usual, and will rely on case-based presentations by experts to cover the main categories of brain, muscle and peripheral nerve disorders. We are convinced that this course, designed for residents and fellows, will also be of interest to experienced pathologists.

A variety of topics have been chosen for the main plenary sessions of the congress to span the different facets of pathology, including lung, gastrointestinal and hepatic diseases, immunopathology and pediatric pathology, embracing a range of neoplastic and non-neoplastic disorders. A distinguished panel of national and international experts has been invited to present their research, share their experience and provide practical guidance. Hematopathology is given special recognition due to recent updates in the classifications of neoplastic entities and will be the focus of a session and slide seminar on Saturday, November 11th.

The meeting will take place at the Beaulieu Convention Center, which is ideally located in the center of the Olympic capital, with a spectacular view over the Lac Léman and the Alps. Lausanne is a very attractive venue and we hope that participation in the meeting will provide you with an opportunity for an enjoyable stay in the Lemanic region. Lausanne is a historical city with museums, cultural attractions, but it also offers lively nights, shopping and renowned gastronomy. This time of the year, the terraced vineyards of Lavaux, a UNESCO World Heritage Site, offer a spectacular panorama not to be missed.

We look forward to meeting you all in Lausanne and to spending quality time together.

Sincerely,

Prof. Dr Laurence de Leval
Congress President, Local organizer

Prof. Dr Viktor Kölzer
Congress Vice-President

TAGRISSE[®]

more precise, earlier, more effective*



The only EGFR TKI approved for the treatment of early and advanced stage EGFRm NSCLC¹

ADJUVANT TAGRISSE^{®1}

-73% reduced risk of recurrence or death versus the control arm in patients with resected EGFRm NSCLC in stage IB-IIIa^{2*}

HR=0.27 (95% CI: 0.21-0.34)²

FIRST-LINE TAGRISSE^{®1}

38.6 vs 31.8 months median OS compared to EGFR TKI comparator arm gefitinib/erlotinib in patients with advanced EGFRm NSCLC³

HR=0.80 (95.05% CI: 0.64, 0.997; P=0.0462)³



TAGRISSE[®]
osimertinib

CI = Confidence Interval; HR = Hazard Ratio; OS = Overall Survival; PFS = Progression Free Survival

*More precise: TAGRISSE[®] is an irreversible inhibitor of EGFR receptors with activating mutations, as well as EGFR T790M resistance mutation, showing only minimal activity against wild-type EGFR.^{1,4} Earlier: TAGRISSE[®] is the only TKI that can be used as adjuvant treatment in EGFRm NSCLC in stages IB-IIIa following R0 resection.¹ More effective: In a head-to-head comparison with gefitinib/erlotinib in the FLAURA study, TAGRISSE[®] showed a median PFS of 18.9 months (vs 10.2 months) and a significant prolongation of the median overall survival to 38.6 months (vs 31.8 months).^{3,4}

1. TAGRISSE[®] Information for Healthcare Professionals. www.swissmedicinfo.ch. 2. Tsuboi M, et al; Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm), stage IB-IIIa non-small cell lung cancer (NSCLC): updated results from ADAURA. Presentation at the European Society of Medical Oncology (ESMO) Congress; 2022 September 9-13; Paris, France. 3. Ramalingam SS, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020; 382:41-50. 4. Cross DAE, et al. AZD5291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046-1061. 5. Sorla JC et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378(2) [in]. Appendix: 113-125.

TAGRISSE[®] Comp: Osimertinib. 40 mg and 80 mg film-coated tablets; List A. **Ind:** TAGRISSE[®] is indicated for the adjuvant treatment after complete tumour resection in adult patients with non-squamous, non-small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) exon 19 deletions or exon 21 (L858R) substitution mutations, for the first-line treatment in adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as well as for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR-T790M mutation who have progressed on or after EGFR TKI therapy. **Dose:** 80 mg once daily. Dose adjustment to 40 mg once daily possible. **CI:** Hypersensitivity to the active substance or to any of the excipients. Concomitant use of St. John's Wort. **W&P:** Interstitial lung disease, QTc interval prolongation, LVEF and cardiomyopathy. Keratitis. Diarrhoea. Age and body weight. Developmental toxicity. **IA:** Strong CYP3A4 inducers. CYP3A4 substrates and transporters. **ADRs:** Very common: diarrhoea, stomatitis, rash, dry skin, paronychia, pruritus, platelet count decreased, leukocytes decreased, lymphocytes decreased, neutrophils decreased. **Common:** Interstitial lung disease, blood creatinine increased, epistaxis, palmar-plantar erythrodysesthesia syndrome, alopecia, urticaria. Uncommon, rare, very rare: see www.swissmedicinfo.ch. **Date of revision of the text:** September 2022. **Further information:** www.swissmedicinfo.ch or AstraZeneca AG, Neuhofstrasse 34, 6340 Baar, Switzerland. www.astrazeneca.ch. Professionals can request the mentioned references from AstraZeneca AG.

Organization

Congress Presidents

Laurence de Leval, Lausanne
Viktor Kölzer, Zurich

Organizing Committee

Sabina Berezowska, Lausanne
Stefan Dirnhofer, Basel
Ekkehard Hewer, Lausanne
Bettina Sobottka-Brillout, Zurich
Inti Zlobec, Bern

Abstract Committee

Ekkehard Hewer, Lausanne
Rainer Grobholz, Aarau
Igor Letovanec, Sion
Thomas McKee, Geneva
Thomas Menter, Basel
Kirsten Mertz, Liestal
Samuel Rotman, Lausanne
Anne Laure Rougemont, Geneva
Niels Rupp, Zurich
Wiebke Solass, Bern

Poster Prize Committee

Matthias Matter, Basel, president
Carmen Barcena, Lausanne
Essia Saiji, Geneva
Rossella Sarro, Locarno
Giulia Tochtermann, St.Gallen

SGPath/SSPath Board

President

Sylvia Höller, Zurich

Vice President

Philipp Went, Chur

Secretary General

Zsuzsanna Varga, Zurich

Administration SGPath/SSPath

Jae Kyoung Pak, Zurich

Quality Management

Joachim Diebold, Lucerne

Representative Molecular Pathology

Thomas McKee, Geneva

Representative Cytopathology

Jessica Barizzi, Locarno

Representative Training and Continuous education

Peter Bode, Winterthur

Tariff: DRG, Tarmed

Davide Soldini, Zurich

General information

Congress venue

Centre de congrès Beaulieu Lausanne
Beaulieu SA, Av. des Bergières 10, 1004 Lausanne
www.beaulieu-lausanne.com

Registration & Congress management

Meeting-com Congress Organisation
Rue des Pâquis 1 • CP 100
CH-1033 Cheseaux-sur-Lausanne
T 021 312 92 62 • nicole.giacomini@meeting-com.ch



Online registration on
www.meeting-com.ch

Onsite registration also possible (onsite fee)

Registration fees

HALF-DAY POST-GRADUATE COURSE Thursday, November 9

Participant – if registered for the congress
Participant – half-day course only

Early fee

(until Oct 8, 2023)

☐ free of charge
☐ 100.00 CHF

Late fee & onsite

(as of Oct 9, 2023)

☐ free of charge
☐ 120.00 CHF

SGPATH ANNUAL MEETING & SLIDE SEMINARS Thursday, November 9 as from 13.00 – to Saturday, November 11, 2023

Junior SSPath members
Residents/students/technicians (non-members)*
SSPath members
SSPath non-members

Early fee

(until Oct 8, 2023)

☐ 120.00
☐ 180.00
☐ 280.00
☐ 450.00

Late fee & onsite

(as of Oct 9, 2023)

☐ 160.00
☐ 220.00
☐ 320.00
☐ 550.00

** Please send a proof of resident/student/technician status to info@meeting-com.ch within 7 days of registration*

SLIDE SEMINAR ONLY Saturday, November 11, 2023

SSPath members (regular and junior members)
Residents/students/technicians (non-members)*
SSPath non-members

☐ free of charge
☐ 80.00
☐ 120.00

CONGRESS DINNER

Participant

FRIDAY, 10.11.2021
Beaulieu Lausanne
☐ 100.00 (TTC)

Included in registration fee

Access to the half-day post-graduate course & the congress, certificate of attendance, badge, coffee-breaks & lunches, according to the program. The congress dinner is NOT included and must be registered separately (as above).

Payment/confirmation

After your registration/payment you will receive our invoice / confirmation by e-mail to the address provided at the time of registration.

Cancellation

Written notification is required for all cancellations and changes. In case of cancellation 30 days prior the event, the refund of the amount paid will be done net of CH 60.00 for administrative costs. Thereafter no refund is possible. Any registration made within the “early bird” time must be paid during this period. If not the case, the invoice is automatically updated at the current price. Administrative costs will be charged to no shows. Legal jurisdiction is Lausanne.

Abstract submission

on the link <https://sgpath2023.exordo.com>

Deadline of submission

September 3, 2023 (midnight CET)

Free paper presentations

2 free paper presentations:
– on Thursday 9.11.23 at 14.40
– on Friday 10.11.23 at 13.45

E-Poster sessions

3 moderated E-poster sessions:
– on Thursday 9.11.23 at 15.15
– on Friday 10.11.23 at 9.30 and at 12.30

Slide seminar

Slide seminar part I and part II:
– on Saturday 11.11.23 at 9.45 and at 12.00

Language

The language of the congress is English.

Award Prizes

The winners of the 3 Best Poster Awards will be announced during the Award ceremony on Friday 10.11.23 at 18.00, with a bursary of:
– 1st Prize: CHF 1'000.00
– 2nd prize: CHF 800.00
– 3rd Prize: CHF 500.00

CME Credits

Credit points given by the Swiss Society of Pathology:

Half-day post graduate course 3 credits


Pathology annual congress (credits on demand at the SGPath Society for)

– Thursday, 9.11.23 5 credits
– Friday, 10.11.23 9 credits
– Saturday, 11.11.23 1.5 credits/half slide seminar
1+1 credit for rendered diagnoses

Certificate of attendance

The certificate of attendance will be sent by email to all participants (slide seminars and diagnoses included) after the event.

How to find the venue



Congress venue

Beaulieu Convention Centre SA
Avenue des Bergières 10
1004 Lausanne
www.beaulieu-lausanne.com

Access by car

Exit A9 freeway "Lausanne Blécherette"
The centre has an underground parking garage at the entrance

Access by public transport

Bus No 3 and No 21, at 10mn from Lausanne main train station

A wide range of hotel accommodation can be found on the website of Lausanne Tourisme (<https://www.lausanne-tourisme.ch/en/>)

Prolaris®

Prostate Cancer Prognostic Test

Every man with prostate cancer
deserves a better answer


Measure the aggressiveness
of prostate cancer



swiss cancer league

Partner

Prolaris helps you to create an informed and
individualized treatment plan.



Prolaris provides actionable results and makes
treatment decisions easier, for you and your patient.



[Learn more here](#)

Now performed in Swiss pathology labs.

Myriad
genetics

Myriad Genetics GmbH
Leutschenbachstrasse 95
8050 Zurich, Switzerland

www.myriadgenetics.eu
info@myriadgenetics.ch

Thursday, November 9

08.00-09.00

Registration and welcome coffee

Foyer Hall 1

09.00-10.30

HALF-DAY POST GRADUATE COURSE

Room Barcelone

NEUROPATHOLOGY FOR SURGICAL PATHOLOGISTS AND CLINICIANS - PART I

Course organizer: Ekkehard Hewer, Lausanne

Chairs: Ekkehard Hewer, Lausanne and Regina Reimann, Zurich

09.00-09.30

Muscle and Nerve

Johannes A. Lohrbus, Geneva

09.30-10.00

Prion Disease and Autopsy

Regina Reimann, Zurich

10.00-10.30

Neurodegeneration

Tibor Hortobagyi, Zurich

10.30-11.00

Coffee break

Exhibition Hall 1

11.00-12.00

HALF-DAY POST GRADUATE COURSE

Room Barcelone

NEUROPATHOLOGY FOR SURGICAL PATHOLOGISTS AND CLINICIANS - PART II

Chairs: Jean-Philippe Brouland, Lausanne and Johannes A. Lohrbus, Geneva

11.00-11.30

Intraoperative Consultation

Ekkehard Hewer, Lausanne

11.30-12.00

Central Nervous System Tumors

Kristof Egervari, Geneva

12.15-12.45

SPONSORED LECTURE BY ZEISS

Chair: Ekkehard Hewer, Lausanne



Room Barcelone

**12.15-12.45 Confocal Laser Endomicroscopy -
new technology for intraoperative diagnosis**

Jürgen Schlegel, Munich (DE)

12.45-13.30

Lunch snack - visit of the exhibition

Exhibition Hall 1

Thursday, November 9

13.30

Swiss Society of Pathology Congress

Room Barcelone

Opening and welcome

Laurence de Leval, Lausanne

13.40-15.10

PULMONARY PATHOLOGY

Room Barcelone

Chairs: Joachim Diebold, Lucerne; Spasenja Savic, Basel

13.40-14.10

Recent Insights into the Pathology of Acute Lung Injury

Mari Mino-Kenudson, Boston (US)

14.10-14.40

Pathology and Biomarkers of Lung Cancer - What Is New?

Sabina Berezowska, Lausanne

14.40-15.10

Asbestos- and Particle Analysis in Occupational Lung Diseases

Barbara Kuhn, Zurich; Bart Vrugt, Münsterlingen

15.10-15.45

FREE PAPER PRESENTATIONS - SESSION 1

Room Barcelone

Chairs: Igor Letovanec, Sion; Anne-Laure Rougemont, Geneva

15.45-16.15

E-poster area - Room Turin AB

ORAL PRESENTATION OF THE BEST POSTERS - SESSION 1

Chairs: Matthias Matter, Basel; Daniela Kaup, Zurich

15.45-16.15

Coffee break - Visit of the exhibition

Exhibition Hall 1

16.15-17.00

KEYNOTE LECTURE

Room Barcelone

Chairs: Laurence de Leval, Lausanne; Viktor Kölzer, Zurich

15.45-16.30

Cell Nucleus: Morphological and Epigenetic Implications for Cell Fate

Susan Gasser, Lausanne

Thursday, November 9

17.00-18.00

IMMUNOPATHOLOGY

Chairs: Samuel Rotman, Lausanne; tbd

Room Barcelone

17.00-17.30

Inflammatory and Infectious Complications of Immunodeficiency in the Gastrointestinal Tract

Rhonda Yantiss, Miami (US)

17.30-18.00

Machine Learning in Renal Pathology (Transplant and Non-Transplant Settings)

Jesper Kers, Leiden (NL)

18.30-20.00

MEETING OF THE INSTITUTE DIRECTORS & APERITIF RICHE

Room Barcelone

Foyer Hall 2

E-poster viewing in the E-poster area during the whole day

Friday, November 10

07.00-08.00

Registration and welcome coffee

Foyer Hall 1

08.00-09.30

DIGESTIVE AND LIVER PATHOLOGY

Chairs: Giacomo Puppa, Geneva; Christine Sempoux, Lausanne

Room Barcelone

08.00-08.30

Latest Insights in Lower-Gastrointestinal Neoplasia

Heather Dawson, Bern

08.30-09.00

Autoimmune Hepatitis, New Concepts and Criteria

Dina Tiniakos, Athens (GR)

09.00-09.30

Appendiceal Mucinous Tumors

Rhonda Yantiss, Miami (US)

09.30-10.30

ORAL PRESENTATION OF THE BEST POSTERS - SESSION 2

Chairs: Carmen Barcena, Lausanne; Simon Haefliger, Basel

E-poster area - Room Turin AB

09.30-10.30

Coffee break - Visit of the exhibition

Exhibition Hall 1

10.30-12.00

QUANTITATIVE AND FUNCTIONAL PATHOLOGY

Chairs: Viktor Kölzer, Zurich; Inti Zlobec, Bern

Room Barcelone

10.30-11.00

Tumor Board - Multi Omics (Emerging Clinical Standards)

Bettina Sobottka, Zurich

11.00-11.30

Computational Pathology (Connecting to the Slide)

Pierre Moulin, Lausanne

11.30-11.45

Theragnostic Pathology (Connecting to the Image)

Niels Rupp, Zurich

11.45-12.00

Future Drug Testing (Functional Analysis)

Berend Snijder, Zurich

Friday, November 10

12.00-12.30

Co-Sponsored Lecture by 10x GENOMICS & LUNAPHORE

Chairs: Kirsten Mertz, Liestal; Hanna Williams, Bern

Room Barcelone

12.00-12.15

Sponsored by 10x Genomics: Spatial Transcriptomics

Viktor Kölzer, Zurich



12.15-12.30

Sponsored by Lunaphore: Multiplexed Imaging

Inti Zlobec, Bern



12.30-13.30

E-poster area - Room Turin AB

ORAL PRESENTATION OF THE BEST POSTERS - SESSION 3

Chairs: Essai Saiji, Geneva; Rossella Sarro, Locarno

12.30-13.45

Lunch break - visit of the exhibition

Exhibition Hall 1

12.30-13.15

Business meeting of the Swiss Society of Molecular Pathology

Room tbd

13.45-14.30

FREE PAPER PRESENTATIONS - SESSION 2

Chairs: Rainer Grobholz, Aarau; Kirsten Mertz, Liestal

Room Barcelone

14.30-16.00

HEMATOPATHOLOGY

Room Barcelone

Emerging Concepts and Updated Classifications of Hematologic Neoplasms

Chairs: Bettina Bisig, Lausanne; Thomas Menter, Basel

14.30-15.00

Histiocytic Disorders

Jean-François Emile, Boulogne (FR)

15.00-15.30

B-Cell Neoplasms

Stefan Dirnhofer, Basel

15.30-16.00

T and NK-Cell Neoplasms

Laurence de Leval, Lausanne

Friday, November 10

16.00-16.30

Coffee break - visit of the exhibition

Exhibition Hall 1

16.30-18.00

PEDIATRIC PATHOLOGY

Room Barcelone

Chairs: Carole Gengler, Lausanne; Sylvia Höller, Zurich

16.30-17.00

Novel Modalities for Autopsies in Pediatric and Perinatal Deaths

Marta Cohen, Sheffield (UK)

17.00-17.30

Soft Tissue Tumors in Children and Adolescents

Rita Aleggio, Roma (IT)

17.30-18.00

Selected Topics in Adolescent Gynecological Pathology

Tjalling Bosse, Leiden (NL)

18.00-18.15

AWARD CEREMONY

Room Barcelone

Chairs: Matthias Matter, Basel; Chantal Pauli, Zurich

19.30

APERITIF & CONGRESS DINNER

Room St-Moritz

End of the day

E-poster viewing in the E-poster area during the whole day

Saturday, November 11

07.00-08.00

Registration and welcome coffee

Foyer Hall 2

08.00-09.30

GENERAL ASSEMBLY SGP/SSP

Room Barcelone

09.30-10.00

Coffee break

Foyer Hall 2

10.00-11.20

SLIDE SEMINAR 1 - HEMATOPATHOLOGY - PART I

Room Barcelone

Lymphoid and Histiocytic Proliferations in Extranodal Sites: Challenges and Pitfalls in Surgical Pathology

Organizers: Laurence de Leval, Lausanne and Stefan Dirnhofer, Basel

Chairs: Laurence de Leval, Lausanne; Luca Mazzucchelli, Locarno

Case 1 Jean-François Emile, Boulogne (FR)

Case 2 Marco Bühler, Zurich

Case 3 Stefan Dirnhofer, Basel

Case 4 Bettina Bisig, Lausanne

Case 5 Jean-François Emile, Boulogne (FR)

11.20-11.50

Sandwich break

Foyer Hall 2

11.50-13.10

SLIDE SEMINAR 2 - HEMATOPATHOLOGY - PART II

Room Barcelone

Chairs: Stefan Dirnhofer, Basel; Esther Garamvölgyi, Marly

Case 6 Luca Mazzucchelli, Locarno

Case 7 Laurence de Leval, Lausanne

Case 8 Thomas Menter, Basel

Case 9 Thomas A. McKee, Geneva

Case 10 Yara Banz, Bern

13.10

Farewell words

Laurence de Leval, Lausanne

End of the Annual Meeting 2023





Retsevmo[®], the first highly selective therapy for patients with certain *RET*-driven tumors¹

For patients with disease progression after a previous treatment¹



Metastatic *RET* fusion-positive NSCLC¹



Advanced *RET* fusion-positive thyroid cancers (non-MTC)¹



Advanced *RET*-mutant MTC¹

RET = REarranged during Transfection; NSCLC = non small cell lung cancer; MTC = medullary thyroid cancer

References: 1. Retsevmo[®] Professional information. www.swissmedinfo.ch

Health Care Professional can request the references from the company at any time.

Retsevmo[®] (selpercatinib): Hard capsule.

I: As monotherapy for the treatment of: adults with metastatic *RET* fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy and have progressed following prior treatment, advanced *RET* fusion-positive thyroid cancer who require systemic therapy and, have progressed following prior treatment including radioactive iodine adults, and adolescents 12 years and older with advanced *RET*-mutant medullary thyroid cancer (MTC) who require systemic therapy and have progressed following prior treatment with tyrosine kinase inhibitors. The efficacy and safety of Retsevmo in patients with additional oncogenic driver mutations have not been evaluated. **P/U:** The recommended dosage of Retsevmo based on body weight is: less than 50 kg: 120 mg, 50 kg or greater: 160 mg, orally twice daily (approximately every 12 hours) until disease progression or unacceptable toxicity. **CI:** Hypersensitivity to the active substance or to any of the excipients listed in «Composition». **W/P:** Increased ALT/AST, hypertension, QT Interval Prolongation, hemorrhagic events, hypersensitivity, risk of impaired wound healing, fertility, concurrent oncogenic driver mutations. **IA:** Selpercatinib can influence sensitive CYP2C8 and CYP3A4 substrates concentration. Strong CYP3A4 inhibitors may increase Selpercatinib plasma concentration. Selpercatinib plasma concentration may be decreased by strong CYP3A4 inducers. Selpercatinib has pH-dependent solubility, with decreased solubility at higher pH that can result in a loss of efficacy. **P/L:** Use a reliable contraception during treatment and for at least 2 weeks after the last dose of selpercatinib. Only be used during pregnancy if the potential benefit justifies the potential risk to the foetus. Pregnant women should be informed about the risk to the foetus. Breastfeeding should be discontinued during treatment with Retsevmo and for at least 2 weeks after the last dose. The effect of Selpercatinib on human fertility is unknown. Based on results from nonclinical safety studies, Retsevmo may compromise male and female fertility. **UE:** Hypersensitivity, decreased appetite, magnesium decreased, headache, dizziness, electrocardiogram QT prolonged, hypertension, dry mouth, diarrhoea, constipation, nausea, abdominal pain, vomiting, rash, pyrexia, fatigue, oedema, increased AST, increased ALT, creatinine increased, lymphocyte count decreased, and platelets decreased. **P:** Retsevmo 40 mg: 56, 60 hard capsules, Retsevmo 80 mg: 56, 60, 112, 120 hard capsules. Dispensing category A. Further information is available at www.swissmedinfo.ch. Eli Lilly (Suisse) SA, Ch. des Coquelicots 16, CP 580, 1214 Vernier (GE). V04-2021.

PP-SE-CH-0331/06.2023




This medicine is subject to additional monitoring. For more information, refer to the professional information/patient information of Retsevmo[®] available at www.swissmedinfo.ch.

Lilly

Exhibition plan

MAIN ENTRANCE



1. UNILABS
2. ROCHE DIAGNOSTICS
3. BIOSYSTEMS
4. BÜHLMANN LABORATORIES
5. BIOCARTIS
6. EXACT SCIENCES
7. EIZO
8. ZYTOMED SYSTEMS
9. TELEMIS
10. STEMLINE
11. RUWAG
12. CELERATO
13. AGILENT TECHNOLOGIES
14. SYNLAB
15. BASYS DATA
16. ASTRAZENECA
17. HOLOGIC
18. INDICALABS
19. IBEX MEDICAL ANALYTICS
20. EVIDENT SCIENTIFIC
21. LUNAPHORE
22. PHILIPS
23. PRECIPOINT
24. MEDITE
25. CARL ZEISS AG
26. HISTOCOM
27. AXONLAB
28. MSD
29. SYSMEX
30. HAMAMATSU
31. WEST MEDICA
- 32.

Kind thanks to our sponsors



Save the dates

2024

Joint Annual Meeting
of the SGPath and ÖGPath 2024

SGPath General Assembly

September 26 to 28, 2024

Feldkirch (A)

2025

89th Annual Congress
of the Swiss Society of Pathology

3rd Swiss Pathology Days

November 20 to 22, 2025

Congress Kursaal Interlaken



Organisation www.meeting-com.ch